Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 28, 2011; 17(16): 2159-2160
Published online Apr 28, 2011. doi: 10.3748/wjg.v17.i16.2159
Published online Apr 28, 2011. doi: 10.3748/wjg.v17.i16.2159
Enucleation for gastrointestinal stromal tumors at the esophagogastric junction: Is this an adequate solution?
Nadia Peparini, Giovanni Carbotta, Piero Chirletti, Department of General Surgery “Francesco Durante”, La Sapienza University, viale del Policlinico 155, 00161 Rome, Italy
Author contributions: Peparini N and Chirletti P contributed equally to this manuscript, conceived and drafted the manuscript, critically revised the manuscript and gave its final approval; Carbotta G contributed to the manuscript draft and gave its final approval.
Correspondence to: Nadia Peparini, MD, PhD, Department of General Surgery “Francesco Durante” viale del Policlinico 155, 00161 Rome, Italy. nadiapeparini@yahoo.it
Telephone: +39-339-2203940 Fax: +39-6-49970385
Received: October 16, 2010
Revised: December 17, 2010
Accepted: December 24, 2010
Published online: April 28, 2011
Revised: December 17, 2010
Accepted: December 24, 2010
Published online: April 28, 2011
Abstract
The authors discussed the proposal by Coccolini and colleagues to treat gastrointestinal stromal tumors (GISTs) at the esophagogastric junction with enucleation and, if indicated, adjuvant therapy, reducing the risks related to esophageal and gastroesophageal resection. They concluded that, because the prognostic impact of a T1 high-mitotic rate on esophageal GIST is worse than that of a T1 high-mitotic rate on gastric GIST, enucleation may not be an adequate surgery for esophagogastric GISTs with a high mitotic rate in which the guarantee of negative resection margins and adjuvant therapies can be the only chance of survival.